Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

DISEASE CHARACTERISTICS: * Undergoing a non-myeloablative allogeneic hematopoietic stem cell transplantation * Must be able to start prophylactic antifungal therapy within 48 hours of the transplantation chemotherapy preparative regimen and before the initiation of cyclosporine * No diagnosis of deeply invasive fungal infection based on the MSG/EORTC criteria PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Bilirubin no greater than 5 times upper limit of normal (ULN) * AST and ALT no greater than 5 times ULN * Alkaline phosphatase no greater than 5 times ULN Renal * Not specified Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for 4 weeks (12 weeks for males) after study participation * Able to swallow oral medication * Sufficient venous access * No prior anaphylaxis attributed to the azole class of antifungals * No concurrent medical condition that may create an unacceptable additional risk for the patient during study participation PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics Chemotherapy * Not specified Endocrine therapy * No concurrent hormonal contraceptives Radiotherapy * Not specified Surgery * Not specified Other * At least 2 weeks since other prior non-FDA approved investigational drugs * No concurrent QTc prolonging medication (e.g., t…